Becton, Dickinson and Co. | BDX - Cash And Equivalent


Becton, Dickinson and Co. reported $813M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Agilent USD 1.81B 49M Mar/2026
Align Technology USD 1.06B 35.07M Mar/2026
AngioDynamics USD 41.64M 14.26M Sep/2025
Avanos Medical USD 65.6M 24.2M Mar/2026
Baxter International USD 2.02B 51M Mar/2026
Becton, Dickinson and Co. USD 813M 73M Mar/2026
Bio-Rad Laboratories USD 507.2M 22.6M Mar/2026
Boston Scientific USD 1.45B 512M Mar/2026
Cooper Companies USD 124.9M 14.3M Dec/2025
Danaher USD 5.7B 1.09B Mar/2026
Dentsply International USD 190M 136M Mar/2026
Dexcom USD 1.12B 200.5M Mar/2026
Edwards Lifesciences USD 2.4B 538M Mar/2026
Globus Medical USD 560.95M 34.79M Mar/2026
Insulet USD 480.4M 235.7M Mar/2026
Integra LifeSciences USD 236.81M 1.76M Mar/2026
Intuitive Surgical USD 7.98B 1.05B Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Medtronic USD 1.15B 135M Dec/2025
Solventum Corp USD 561M 317M Mar/2026
Stryker USD 2.88B 1.13B Mar/2026
Tandem Diabetes Care USD 179.32M 88.69M Mar/2026
Teleflex USD 309.41M 69.15M Mar/2026
Terumo JPY 217.16B 12.86B Sep/2025
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Zimmer Biomet Holdings USD 424.2M 167.7M Mar/2026